Session length, staffing, support requirements and repeat dosing may determine which treatments reach patients at scale.
Psychedelic drugs are moving closer to FDA approval. Now comes the harder test: building treatment models that healthcare systems can actually deliver.
That challenge was the focus of a recent FDA public hearing on the potential therapeutic use of psychedelic drugs in supervised settings. The agency sought input on provider training, patient monitoring, insurance coverage and long-term safety.
Those questions suggest the real competition may not be over which psychedelic is most effective, but over what happens around each dose.
Compass Provides Support in the Model
Compass Pathways is developing COMP360, a synthetic formulation of psilocybin, for treatment-resistant depression.
In its Phase 3 COMP005 trial, Compass reported rapid onset and durable improvement after a 25-milligram dose. More recent open-label results suggest that an additional dose can deepen the response and extend benefit through one year.
Each COMP360 administration occupies a treatment room for six to eight hours. During that session, trained personnel provide nondirective support as part of a structured psychological-support model that includes preparation beforehand and integration afterward. Compass distinguishes this support from psychotherapy, but its model still requires most of a working day and several stages of care.
Compass is already investing in that workforce. In September, the company awarded grants to five organizations to develop training for healthcare professionals involved in delivering psychedelic treatments such as COMP360.
The commercial case depends on durability offsetting the operational burden of each treatment. The treatment room, trained personnel and surrounding support become easier to justify if benefits last for months between administrations.
Compass expects to complete its rolling New Drug Application in the fourth quarter of 2026. The FDA review will help determine how much of that support model follows the drug into clinical practice.
Definium Strips the Model Back
Definium Therapeutics is developing DT120, an orally disintegrating formulation of lysergide, or LSD, for generalized anxiety disorder and major depressive disorder. Those indications represent different and potentially broader patient populations than Compass’s treatment-resistant depression program.
DT120 has demonstrated improvement within days of a single administration, with effects maintained through the 12-week controlled evaluation period.
Definium’s clearest operational distinction is its effort to deliver DT120 as a standalone drug. Rather than pairing treatment with preparation or integration support, its proposed patient journey centers on clinical screening, monitoring during dosing and follow-up assessments.
That does not eliminate the time requirement. According to the phase 3 Panorama results, participants receiving 100 micrograms required an average of 6.2 hours to meet the criteria for ending the session. Across more than 1,000 Phase 3 treatment sessions, 97% met those criteria within eight hours.
DT120 could therefore reduce the number and complexity of professional interactions surrounding psychedelic treatment without freeing the treatment room itself. Definium has scheduled a pre-NDA meeting with the FDA for the fourth quarter of 2026 and anticipates filing for approval in the first half of 2027.
GH Research Attacks the Clock
GH Research is pursuing a completely different treatment model. Its lead program, GH001, is an inhaled formulation of mebufotenin for treatment-resistant depression.
GH001 produced significantly greater improvement than placebo in a Phase 2b trial. GH Research does not require psychotherapy, and unlike either Definium or Compass, it is trying to reduce the time spent in the clinic.
The company has reported a median psychoactive experience of approximately 11 minutes, with 99% of treatment visits ending within one hour.
A room used for one COMP360 or DT120 administration could potentially accommodate several GH001 visits. Shorter sessions could also reduce staffing requirements and allow treatment to fit more naturally within existing interventional psychiatry practices.
The tradeoff is repeat treatment. GH Research reported approximately four treatments on average over six months. That is more frequent than a model built around one or two extended administrations, although each visit may be substantially easier to accommodate.
GH Research is now preparing to test that proposition in a pivotal program. After the FDA lifted a clinical hold in January, the company completed two supporting Phase 1 studies, selected doses for the pivotal trials and received FDA feedback indicating that its manufacturing and proprietary-device plans are ready for Phase 3. Its latest update continued to target initiation of the global program in 2026.
Approval Is Only the First Test
The FDA hearing showed how far the psychedelic discussion has moved. Clinical efficacy remains fundamental, but regulators, providers and patients are also confronting who will supervise treatment, what training those people need, how patients should be monitored and whether insurers will cover both the drug and the services required to deliver it.
The three companies offer different answers. Compass accepts preparation, supervision, follow-up and a long administration session in pursuit of durable benefit with infrequent treatment. Definium removes preparation and integration services but retains a visit lasting much of the day. GH Research compresses the visit but may require patients to return more often.
Those differences will shape where the drugs can be administered, how many patients a clinic can treat, which professionals must be involved and what payers are being asked to reimburse.
The molecule may earn approval. The treatment model will determine adoption.